Vaccination is recommended for patients undergoing allogeneic haematopoietic stem cell transplantation (SCT) once their immune system recovers not only for their own benefit but also for that of susceptible infants and young children to prevent transmission of diseases. As no specific trials have been done in SCT recipients, they are vaccinated similarly to immunocompetent individuals with the exception of live virus vaccines. 1 Cord blood transplantation (CBT) is being used increasingly to treat patients with haematological malignancy. Since cord blood cells are unprimed, CBT recipients are also believed to need vaccination. Pertussis vaccine, however, has not been normally recommended for older children, that is, over 7 years old because of the decreased severity of pertussis with age, and of increased adverse reactions to pertussis vaccine in immunocompetent hosts. 2 To our knowledge, there is no report of the severity of pertussis infection or adverse reactions of pertussis vaccination in SCT recipients. Here, we describe a case of pertussis patient after unrelated CBT.
He was diagnosed as having infantile acute lymphoblastic leukaemia without a MLL gene rearrangement at 6 months old, and was successfully treated with chemotherapy. He remained leukaemia free for about 6 years, but bone marrow relapse occurred at 7 years old. He achieved complete remission again with chemotherapy. As there was no major histocompatibility complex-matched related or unrelated BMT donor, he underwent one antigen-mismatched unrelated CBT at the age of 10 years. Preparative regimen consisted of busulphan-based chemotherapy and graft-versus-host-disease (GVHD) prophylaxis consisted of cyclosporin (CsA) alone. Haematological engraftment was completed by day 59 after transplantation. No acute or chronic GVHD was observed and CsA was tapered and stopped by day 59. He received diphtheria and tetanus vaccination twice 1 year after transplantation, and live polio and measles vaccines 2 years after transplantation without any complications. At 31 months after transplantation, he complained of a productive cough with sleep disturbance for about 1 week. Chest X-ray revealed only slightly emphysematous lungs, and computer tomography showed no abnormality. Laboratory findings revealed only an elevated white blood cell count at 10.8 Â 10 9 /l with 58% lymphocytes. Severe dry cough, disturbing his sleep, persisted for the next 7 weeks. Medications including antitussives, narcotics, bronchodilators and antiallergic agents had no effect. During this period, cephalosporine and then clarithromycine were tried for about 5 days each without success. Serological examination failed to reveal any specific pathogen relating to his cough except pertussis. His pertussis agglutination antibody titre was positive (1 : 160) 1 week after the onset of cough and rose to a titre of 1 : 640 at 4 weeks. These titres strongly suggested pertussis as the cause of his sustained cough, although culture for isolation of Bordetella pertussis was not done.
Recent acellular pertussis vaccine has a lower frequency of adverse events compared with whole-cell pertussis vaccine; however, data are insufficient to assess the safety of this vaccine in older children. 3 The severity and duration of his pertussis were comparable to that of young children, although there were no complications relating to pertussis. We should consider vaccination with acellular pertussis vaccine for patients after SCT, especially after CBT, even if they are beyond their seventh birthday, or adults. N Suzuki N Mizue T Hori N Hatakeyama T Kudoh H Tsutsumi
